Skip to main content

Company Overview

480 Biomedical is a clinical stage company developing novel bioresorbable scaffold technologies for the vasculature. 480 Biomedical was founded to advance clinical-stage scaffold technologies from Arsenal Medical.

Learn more about Arsenal Medical at

Bioresorbable Scaffold Technology

480 Biomedical's self-expanding scaffold technology platform employs a unique composite design that strikes an optimal balance of strength, flexibility and bioresorption.

Lead Product: Peripheral Artery Disease

Our lead product is the proprietary Stanza™ bioresorbable, drug eluting, scaffold and delivery system for use in treating peripheral artery disease in the superficial femoral artery, a condition that is poorly addressed today.


480 Biomedical Announces Funding From Broadview Ventures for Development of Pediatric Scaffold

June 18, 2015

View press release

Arsenal Medical and 480 Biomedical Raise $26.5 Million in Combined Funding for Development of Novel Products to Treat Vascular Disease and Abdominal Trauma

June 1, 2015

View press release

480 Biomedical Awarded $1 Million Phase II NHLBI Contract to Advance Bioresorbable Scaffold for Pediatric Pulmonary Artery Stenosis

July 9, 2014

View press release

BSI Certificate Awarded

December 11, 2013

View press release